Across TCGA pan-cancer cohorts, SECISBP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SECISBP2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SECISBP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SECISBP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where SECISBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	III,IV	0.901	0.478	.019	3	view →
LUAD	DFS	Quartile	II,III,IV	0.470	0.869	.033	2	view →
HNSC	DFS	Quartile	III,IV	1.000	0.666	.030	2	view →
CCRCC	OS	Median	All	0.892	0.613	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SECISBP2 tumor-vs-normal RNA expression · all SECISBP2 data types